Introduction
============

The incidence of thyroid cancer has increased worldwide at a rate higher than any other cancer. Papillary thyroid cancer (PTC) is the most ordinary endocrine malignancy and accounts for 80% cases of differentiated thyroid cancer [@B1]. In line with the majority of malignancies, thyroid carcinomas are also correlated with specific genetic abnormalities which lead to aberrant cell proliferation. With the rising trends in the incidence of PTC have been well-recognized, the need to develop new treatments is more acute than ever.

Yes associated protein 1 (YAP1) gene is located in the 11q22 amplicon, which is the main nuclear coactivator in the Hippo pathway [@B2]. Dysregulation of Hippo pathway, as a key oncogenic signal which malignancy cells rely on, could result in permanent activation of pro-tumor signal cascade [@B3], [@B4]. Therefore, modulating the Hippo pathway pathway presents an attractive anti-cancer strategy. The small molecule inhibitor of YAP1 [@B5], verteporfin (VP), a benzoporphyrin derivative approved for photodynamic therapy to eliminate the age-related macular degeneration, may function as a potential candidate for cancer treatment. Indeed, its antitumor effect has been validated in multiple types of cancer, such as pancreatic cancer, breast cancer and colon cancer [@B5]-[@B8], but the role of VP plays in PTC has not yet been known.

Our previous works showed that YAP1, as an oncogene in PTC, could promote cell proliferation of PTC cells via ERK/MAPK signalling pathway [@B9]. In present study, we demonstrated VP can inactivate ERK1/2 and MEK phosphorylation to inhibit proliferation and arrest G1/S cell cycle of PTC cells. Therefore, we supposed that tumor suppressive function of VP make it be a promising potential strategy for treatment of PTC.

Results
=======

Inhibitory effect of verteporfin on the proliferation of papillary thyroid cancer cells *in vitro* and *in vivo*
----------------------------------------------------------------------------------------------------------------

To access the role of verteporfin on the proliferation of papillary thyroid cancer cells, we firstly treated PTC cell lines K1 and BCPAP with 0.5 μM, 1 μM or 5 μM verteporfin or DMSO. CCK8 proliferation was then used to estimate cell viability of the treated cells. As shown in Fig. [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B, both K1 and BCPAP cell viability were inhibited by verteporfin treatment, and the inhibitory effect displayed a dose dependent manner.

The proliferation related gene expression of survivin, PCNA, and c-Myc were decreased in verteporfin-treated K1 and BCPAP cells (Fig. [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}D). Western blotting analysis showed the expression level of protein (survivin, PCNA, and c-Myc) in both K1 and BCPAP cells were downregulated after the treatment of verteporfin (Fig. [1](#F1){ref-type="fig"}E and [1](#F1){ref-type="fig"}F), which was also in a dose-dependent manner. 1 μM and 5μM verteporfin treatment for 72h seems to be more effective than 0.5 μM in both K1 and BCPAP cells. The results revealed that verteporfin could significantly inhibit the cell proliferation of papillary thyroid cancer cell.

To further determine the anticancer effect of verteporfin on papillary thyroid cancer *in vivo*, 1x10^7^ K1 cells were subcutaneously interjected into nude mice. After 14 days, the transplanted xenograft tumors were constructed. verteporfin (100mg/kg) was intraperitoneally injected into the mouse in verteporfin-treated group (K1+VP) every 3 day, while mouse in vehicle-group treated with PBS. Animals were sacrificed after five doses of verteporfin and tumor volumes were measured (Fig. [2](#F2){ref-type="fig"}A). The verteporfin-treated mice generated tumors were dramatically smaller than the tumors present in vehicle-group mice (Fig. [2](#F2){ref-type="fig"}B and C). The tumors were formalin-fixed and paraffin-embedded and tumor tissue sections were analyzed by IHC. The positive number of Ki67+ cells revealed verteporfin treatment significantly suppressed the proliferation of the implanted tumors (Fig. [2](#F2){ref-type="fig"}D and E). In a word, the data indicated that VP can inhibit proliferation and growth of papillary thyroid cancer *in vitro* and *in vivo*.

Verteporfin induces apoptosis of papillary thyroid cancer cells
---------------------------------------------------------------

Next, we examined whether verteporfin could induce apoptosis of K1 and BCPAP cells. After treated with 0.5 μM, 1 μM or 5 μM verteporfin or DMSO, apoptotic cells were analyzed by flow cytometry (Fig. [3](#F3){ref-type="fig"}A and B). Compared with DMSO-treated group (8.87 ± 1.53% of K1 and 11.17 ± 2.59% of BCPAP), 0.5 μM verteporfin induced about 13.8 ± 1.53% in K1 and 17.47 ± 2.59% in BCPAP (*P* \> 0.05), while 1 μM and 5μM verteporfin induced about 30.93 ± 3.63% and 80.66 ± 2.03% in K1 (*P* \< 0.05), 28.6 ± 6.391% and 85.32 ± 3.822% in BCPAP (*P* \< 0.05), respectively. The results showed that the apoptosis rate of K1 and BCPAP increased when the concentration of verteporfin increased. Moreover, both caspase 3 and cleaved-caspase 3 were activated in a dose-dependent manner in verteporfin-treated K1 and BCPAP cells (Fig. [3](#F3){ref-type="fig"}C).

Verteporfin arrests G1/S phase of papillary thyroid cancer cells through cyclin A2 and p21
------------------------------------------------------------------------------------------

The above data suggested that 1 μM verteporfin could significantly inhibit proliferation and induce apoptosis of K1 and BCPAP cells. Thus, we further verify whether 1 μM verteporfin affected cell cycle progression. Firstly, K1 and BCPAP cells were treated with 1 μM for 48 h, and then cell cycle was accessed using flow cytometry assay. As shown in Fig. [4](#F4){ref-type="fig"}A and B, the treated K1 cells had a low percentage of G0/G1 phase (50.3%) and high percentage of G1/S phase (29.63%) compared with control group (61.4% and 20.24%), while the treated BCPAP cells also had a low percentage of G0/G1 phase (47.37%) and a high percentage of G1/S phase (30.19%) compared with control group (59.76% and 20.46%), respectively. G2/M phase of treated K1 and BCPAP cells were 19.95% and 19.31%, control group had 16.05% and 17.8% G2/M phase, respectively. It suggested that both K1 and BCPAP cells were arrested in G1/S phase by 1 μM verteporfin. Next, we examined the expression of cyclin A2 and p21 in verteporfin-treated K1 and BCPAP cells, which have a key role in the cell cycle. Western blotting analysis data showed that the expression of cyclin A2 and p21 were enhanced after verteporfin treatment, exhibiting a dose-dependent manner (Fig. [4](#F4){ref-type="fig"}C).

Verteporfin inhibits proliferation and cell cycle of papillary thyroid cancer cells through ERK1/2 signalling pathway
---------------------------------------------------------------------------------------------------------------------

Verteporfin is known as a YAP1 inhibitor, independent of light activation [@B10]. Here, we accessed the expression level of YAP1 in treated K1 and BCPAP cells. As shown in Fig. [5](#F5){ref-type="fig"}A and B, both mRNA and protein level of YAP1 in K1 and BCPAP cells dramatically decreased after 1 μM verteporfin treatment. To further explore the underlying signaling involved in the inhibitory effect of verteporfin on thyroid cancer cells, we treated the cells with U0126, a MEK inhibitor, and examined the expression of protein involved in ERK1/2 signaling pathway. The results revealed that the total ERK1/2 and MEK did not change with the treatment of U126, while phosphorylated ERK1/2 and MEK significantly declined in 1 μM verteporfin treated K1 and BCPAP cells. These data suggested that verteporfin exhibit inhibitory effect on PTC cells partly through ERK1/2 signaling pathway.

Discussion
==========

Verteporfin is a second-generation photosensitizer that has been reported to be a candidate of photodynamic therapy for the management of vertebral breast metastases [@B5] and locally advanced pancreatic cancer [@B6]. However, there are rare reports about the effect of verteporfin on papillary thyroid cancer and the underlying mechanism. In this study, we displayed verteporfin exhibited inhibitory effect on proliferation and cell cycle, and induced apoptosis of thyroid cancer cells*in vitro*, and it could also suppress thyroid cancer xenograft growth *in vivo*. Our finding indicated that verteporfin may be a therapeutic target to treat thyroid cancer.

After the first preliminary clinical study reported for the treatment of skin cancer [@B11], accumulating evidences have proved that verteporfin is a promising anti-tumor drug against multiple types of solid cancers. Liu-Chittenden Yi et al. group have identified that verteporfin as a small molecule can inhibit the interactions of YAP-TEAD and prevents YAP1-induced oncogenic growth by binding to YAP1 and changing its conformation, thereby abrogating its interaction with TEAD2 [@B12]. In our previous study, we covered that YAP1 played a vital role as an oncogene on the tumorigenicity of PTC [@B9]. To explore the effect of verteporfin on PTC, we complement the data and confirm its inhibitory effect on PTC oncogenesis in current study. YAP1 expression level in PTC cells decreased with the treatment of 1μM verteporfin, which make us speculate that the inhibitory effect of verteporfin may result from its disrupting YAP1\'s function in PTC.

Previous researches showed that MAPK signaling pathway involves in cell proliferation of multiple tumor [@B13]-[@B15], including thyroid cancer. Previous study has detected that verteporfin could block RAS-induced MAPK signaling pathway in ATC cell lines [@B16]. In our previous study, we also found that YAP1 was involved in PTC oncogenesis through MAPK signaling pathway [@B9]. Herein, exposure to MEK inhibitor U0126 could also partly suppressed phosphorylated ERK1/2 and MEK expression in verteporfin-treated PTC cells, further complement with previous study. However, warranting further underlying mechanism investigation is still needed to figure out how verteporfin influence the YAP1-ERK/MAPK crosstalk in the process of PTC.

In conclusion, we for the first time reveal verteporfin inhibits the proliferation and cell cycle of papillary thyroid cancer cells partially via ERK1/2 signaling pathway. Taken together, verteporfin may be an encouraging candidate for the therapeutic management of papillary thyroid cancer.

Methods
=======

Cell culture and treatments
---------------------------

Papillary thyroid cancer cell lines BCPAP and K1 were grown in RPMI1640 media supplemented with 10% heat-inactivated FBS (Invitrogen, Carlsbad, CA, USA) and 1% penicillin-streptomycin (10,000 units penicillin and 10 mg streptomycin) at 37°C with 5% CO~2~. Verteporfin (VP) was dissolved in DMSO (100 mg/mL) and stored at -20°C. BCPAP and K1 cells were treated with dimethyl sulfoxide or VP with a dose of 0.5μM, 1μM or 5μM and U0126 (10 μM) (Sigma Chemical Co., St. Louis, MO).

Total RNA extraction and RT-PCR
-------------------------------

We extracted total RNA of cultured cells with TRIzol Reagent (Invitrogen, Inc.). 1μg of total RNA was utilized for cDNA synthesis in a PrimeScript^TM^ RT reagent kit (Takara Bio, Inc., Japan). qRT-PCR was performed with SYBR Premix Ex Taq^TM^ kit (Takara Bio, Inc., Japan) in triplicate according to the manufacturer\'s instructions. The primers of target genes were synthesized by Sangon Company (Sangon Biotech Co., Ltd., Shanghai, China) (Table [1](#T1){ref-type="table"}). The house keeping gene β-actin was used as endogenous control for mRNA assays. Threshold cycle (Ct) values were analyzed using the comparative Ct (2^-ΔΔCt^) method. The expression of target genes was calculated by normalizing to β-actin and relative to the control.

Western blotting
----------------

Cell lysates from 1 × 10^6^ cultured cells were obtained in a mixture of Proteo^JET^ Mammalian Cell Lysis Reagent (Fermentas, Inc.). A total of 20 μg protein extracted from each sample was separated by 10 % SDS-PAGE. After blocked in 5 % nonfat milk, the target protein was incubated with antibody either against human YAP1 (1:1000; abcam), c-Myc, PCNA (Proliferating cell nuclear antigen, PCNA), survivin, ERK1/2, MEK, phosphorylatd-ERK1/2 and MEK (1:1000; Cell Signaling Technology), or GAPDH (1:5000; Abcam); then incubated with goat anti-rabbit or goat anti-mouse IgG (1:5000 for both; Cell Signaling Technology); and detected using enhanced chemiluminescence reagents (Thermo Fisher Scientific). Target bands were detected using the Alpha Imager (Alpha Innotech, San Leandro, CA, USA).

CCK8 proliferation assays
-------------------------

Cell viability was examined using the Cell Counting Kit-8 (CCK8; Dojindo Molecular Technologies, Gaithersburg, Maryland, USA). In brief, BCPAP and K1 cells were treated with DMSO or VP with a dose of 0.5μM, 1μM or 5μM. The treated cells were seeded into 96-well plates at 4×10^3^ cells/well. An aliquot of 10 μl CCK-8 solution was added into each well, and then was incubated for 4 h at 37 °C. At the indicated time points, the absorbance at 450 nm was measured using a spectrophotometer. For each group, data from five wells were pooled.

Apoptosis assays
----------------

Apoptotic cells were accessed by flow cytometric analysis of Annexin V-FITC/PI staining (BD Biosciences, Mississauga, ON). The cells were cultivated in different concentrations of VP for 48 h, and then trypsined and washed. Resuspended cells were stained with 5 μl Annexin V-FITC and 10 μl PI at room temperature for 15 min (Biovision, CA, USA). After incubation, the cells were then analyzed by flow cytometry immediately. Apoptotic cells were marked based on Annexin V expression (Annexin V+/PI- and Annexin V+/PI+), quantified and compared to the controls from each group. Data from independent triplicate experiments were calculated to analyze the number of apoptotic cells.

Cell cycle analysis
-------------------

In order to synchronize the cell cycle, cells were harvested in ice-cold PBS, and fixed in ice-cold 70% ethanol. The fixed cells were then resuspended in cold PBS. RNAase (2μg/ml) was added and incubated at 37°C for 30 min, followed by cultivation in 400 μl propidium iodide (PI, 10 μg/ml) for 40 min at room temperature. The DNA content was determined by a FACS Calibur flow cytometer and the cells in different phase of G0, G1, S, M were analyzed. All experiments were performed in triplicates.

Animal experiments
------------------

Five weeks old BALB/c nude mice (4 mice/group) were obtained from the Shanghai experimental animal center (Shanghai, China). Briefly, 1x10^7^ K1 cells were subcutaneously injected into the right back skin area of BALB/c nude mice. The size of tumors was measured by vernier caliper once a week. After 14 days, the tumors were constructed, mice were administered intraperitoneally with VP at a dose of 100 mg/kg every 3 day whereas control mice were injected with equivalent PBS. After 5 dose of VP, mice were sacrificed, and tumor tissues were collected, photographed and weighted. Paraffin-embedded tissues were sectioned for immunohistochemistry of Ki-67 (Santa Cruz Biotechnology). Animal experiments have been pre-approved by the Shanghai Cancer Center, Fudan University and all the procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed according to procedures as described previously. In brief, formalin-fixed and paraffin-embedded tissue sections were deparaffinized in xylene and hydrated through descending concentrations of ethanol before being placed in blocking solution to inhibit endogenous peroxidase activity. The slides were incubated with primary antibody at 4°C overnight. A HRP-conjugated rabbit or mouse secondary antibody was added for 60 min at room temperature, followed by 3,3′-diaminobenzidine (DAB) development. Slides were fixed and images obtained with the Olympus IX71 inverted microscope using the DP2-BSW Olympus image acquisition software system. The results were confirmed by two experienced pathologists who were blinded to the clinic pathologic data of the patients. We took 5 visual field per section and number of Ki67 positive cells in each field were calculated to analyze the average of positive Ki67 cells in each group.

Statistics
----------

Statistical analysis was performed with GraphPad Prism 5.1. For comparison among the groups, Student\'s *t* test, one-way ANOVA and two-way ANOVA were performed, and *P*\<0.05 was defined as statistically significant. The data and error bars report the mean ± SEM. All the experiments were repeated at least three times.
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PTC

:   papillary thyroid carcinoma

PCNA

:   proliferating cell nuclear antigen.

![**The effect of verteporfin on the proliferation of PTC cell line K1 and BCPAP.** K1 and BCPAP were treated with 0.5 μM, 1 μM or 5 μM verteporfin or DMSO. Cell viability of treated K1 **(A)** and BCPAP **(B)** were examined by CCK8 assay. The proliferation related genes (survivin, PCNA, and c-Myc) expression were detected in treated K1 **(C)** and BCPAP **(D)** by qPCR. The results are presented as fold-changes in verteporfin treated cells relative to DMSO treated control cells. qPCR results were normalized to β-actin mRNA expression. Western blotting was used to investigate the gene level of proliferation related markers in treated K1 **(E)** and BCPAP **(F).** All the experiments were performed in triplicate. (\**P*\<0.05, \*\*\**P*\<0.001).](jcav09p1329g001){#F1}

![**Verteporfin suppressed tumor growth of papillary thyroid cancer *in vivo*.** 1x10^7^ K1 cells were subcutaneously injected into nude mice, VP (100mg/kg) was intraperitoneally injected every 3 days when transplanted xenograft tumors were constructed. After five doses of VP, tumor volumes were measured. **(A-B)** Four representative tumors from each group (n=4) are shown.**(C)** Volume comparison for tumors from K1-VP group and K1-NC group. **(D)** IHC analysis of Ki67 in formalin-fixed, paraffin-embedded tumors from K1-VP group and K1-NC group (Original magnification ×200; Arrow marked Ki67 positive cells). **(E)** Number of Ki67+ cells in tumors from K1-VP group and K1-NC group. (\**P*\<0.05, \*\**P*\<0.01).](jcav09p1329g002){#F2}

![**Verteporfin induces PTC cell apoptosis *in vitro***. K1 and BCPAP were treated with 0.5 μM, 1 μM or 5 μM verteporfin or DMSO. **(A)** Cell apoptosis was examined by flow cytometry. UL, necrotic cells; UR, terminal apoptotic cells; LR, early apoptotic cells. **(B)** Apoptotic cells of 0.5 μM, 1 μM or 5 μM verteporfin-treated group were quantified to DMSO group. The results are presented as the mean ± SEM from three independent experiments.**(C)** Caspase 3 and cleaved-caspase 3 expression were determined by WB. (\**P*\<0.05, \*\*\**P*\<0.001).](jcav09p1329g003){#F3}

![**Cell cycle inhibition of PTC cells with verteporfin treatment**. K1 and BCPAP were treated with 0.5 μM, 1 μM or 5 μM verteporfin or DMSO.**(A)** Cell cycle distributions of the treated cells were analyzed by flow cytometry. **(B)** Cells of G0/G1, G1/S, G2/M phase were quantified in treated cells. The results are presented as the mean ± SEM from three independent experiments.**(C)** Expression of cyclin A2 and p21 were detected in the treated cells using WB. (\**P*\<0.05, \*\**P*\<0.01).](jcav09p1329g004){#F4}

![**Verteporfin-induced proliferation suppression and cell cycle arrest via ERK1/2 and MEK.** 1 μM verteporfin treatment decreased YAP1 expression in both protein **(A)** and gene level **(B).** qPCR results were normalized to β-actin mRNA expression. **(C)** Treatment of U0126 suppressed the expression of phosphorylated ERK1/2 and MEK in verteporfin-treated K1 and BCPAP cells. (\*\**P*\<0.01). All the experiments were performed in triplicate.](jcav09p1329g005){#F5}

###### 

qRT-PCR primers of target genes

  Target genes   Forward sequence (5\'to3\')   Reverse sequence (5\'to3\')
  -------------- ----------------------------- -----------------------------
  YAP1           TAGCCCTGCGTAGCCAGTTA          TCATGCTTAGTCCACTGTCTGT
  c-Myc          GGAGGCTATTCTGCCCATTT          CGAGGTCATAGTTCCTTGTTGGT
  survivin       CACTTTCTTCGCAGTTTCCT          GACCACCGCATCTCTACATTC
  PCNA           AAACTAGCTAGACTTTCCTC          TCACGCCCATGGCC AGGTTG
  β-actin        TGACGTGGACATCCGCAAAG          CTGGAAGGTGGACAGCGAGG
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